Recent Regulatory Developments India’s biopharmaceutical industry stands at an inflection point where its scientific capabilities and production scale are increasingly recognized globa...
Key Highlights: Implications: Zaynich’s approval gives Wockhardt a home-grown differentiated anti‑infective positioned squarely at India’s metallo‑β‑lactamase (MBL) and XDR Gram‑...
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers...
Key Highlights Implications: Lormalzi gives Lilly an early foothold in India’s tiny but fast‑growing market for disease‑modifying Alzheimer’s drugs, while it test...
Key Highlights: Implications: Wockhardt’s SEC nod for Zaynich marks a major step toward India’s first home-grown, dual‑mechanism anti‑Gram‑negative launched in the carbapenem‑resistan...
Key Highlights: Implications: By pairing one of the lowest weekly price points in the GLP‑1 segment (₹325–₹440) with a vial‑plus‑pen strategy, Glenmark is clearly targeting early initiatio...
Key Highlights: Implications: Qdenga’s positive SEC opinion moves India close to its first widely available dengue vaccine, with import approval tied to a rapid post‑marketing s...
Key Highlights: Implications: This curbs aggressive GLP-1 marketing (e.g., Ozempic/Wegovy), protecting India’s $115M diabetes/obesity segment from off-label hype amid 101M diabetics....
Key Highlights: Implications: Pharma innovators breathe easy as testing bottlenecks vanish, unleashing faster launches for complex biologics and nephrology breakthroughs. Local manufa...
